Hyrnuo (sevabertinib) is an oral targeted therapy used to treat adults with locally advanced or metastatic non-squamous non–small cell lung cancer (NSCLC) that has HER2 (ERBB2) tyrosine kinase domain activating mutations. It is prescribed after patients have received at least one prior systemic therapy. Hyrnuo works by blocking HER2-driven tumor growth and is taken twice daily with food.
To Get Full Access :
